Flora Growth Corp.
11.63-0.05 (-0.43%)
Oct 28, 4:00:00 PM EDT · NasdaqCM · FLGC · USD
Key Stats
Market Cap
8.28MP/E (TTM)
-Basic EPS (TTM)
-34.71Dividend Yield
0%Recent Filings
8-K
ATM offering expanded to $3.45M
Flora Growth Corp. filed a prospectus supplement on September 29, 2025, enabling up to $3.45 million in additional common share sales through its at-the-market program with Revere Securities LLC, effective from September 23, 2025. This replaces the prior supplement, under which the company sold $129,482 in shares. The move bolsters liquidity. Yet dilution looms for shareholders.
8-K
Director's death sparks Nasdaq issues
Flora Growth Corp. disclosed the sudden passing of independent director Harold Wolkin on August 25, 2025, triggering non-compliance with Nasdaq's corporate governance rules. The board now has only two independent directors out of four, falling short of the majority requirement, while the audit committee is down to two members instead of the mandated three independents. The company is evaluating options to regain compliance within the one-year cure period ending August 25, 2026. This lapse risks delisting scrutiny, yet the firm honors Wolkin's contributions.
8-K
1-for-39 share consolidation
Flora Growth Corp. executed a 1-for-39 share consolidation on August 4, 2025, effective from 5:00 p.m. ET the prior day, to adjust its share structure after board approval on July 10. Trading on Nasdaq resumes post-consolidation that morning, with no changes to shareholder rights or ownership percentages. Proportionate adjustments apply to equity awards and warrants. Fractional shares round up, preserving stakes.
10-Q
Q2 FY2025 results
Flora Growth's Q2 revenue dipped 5.7% y/y to $14.8M, with gross profit holding at 19.1% margin amid softer JustCBD sales, yet operating loss narrowed to $2.6M from $3.5M through cost cuts and a $1.2M gain on deconsolidating insolvent subsidiaries. YTD revenue fell 21.1% to $26.6M, but net loss halved to $3.2M versus $6.0M last year, driven by lower expenses and fair value gains. The $2.9M United acquisition in February added $0.4M revenue and $2.4M goodwill, bolstering the house of brands segment. Cash dwindled to $1.5M with $5.6M operating outflow, offset by $1.5M equity raise, while $5.3M debt looms at 5-6% rates. Non-GAAP metrics not disclosed in the 10-Q. Regulatory hurdles in Florida persist as a key risk.
8-K
Shareholders approve plan expansion
Flora Growth Corp. shareholders approved amendments to the 2022 Incentive Compensation Plan at the June 30, 2025 annual meeting, boosting reserved common shares from 2.5 million to 4.5 million. They also greenlit repricing certain stock appreciation rights to $0.58—matching that day's Nasdaq close—and tied vesting to share price jumps in 25% increments up to 225%. This aligns executive incentives with stock performance, yet Proposal 4 for new SAR grants to top officers failed amid mixed votes. Retention hinges on market gains.
IPO
Website
Employees
Sector
Industry
ACB
Aurora Cannabis Inc.
5.01-0.08
CANN
TREES Corporation
0.04-0.00
CGC
Canopy Growth Corporation
1.29-0.03
CNTMF
FLUENT CORP
0.05-0.00
CRLBF
Cresco Labs Inc.
1.20-0.04
CURLF
Curaleaf Hldgs Inc.
2.82-0.05
GHBWF
-
0.53-0.03
GSTK
Growth Stalk Holdings Corp
2.25+0.00
GTBIF
Green Thumb Industries Inc.
7.13-0.28
TCNNF
Trulieve Cannabis Corporation
7.11-0.22